Elena Castro
University of Iceland
CancerPathologyOncologyProstate cancerMedicine
What is this?
Publications 105
#1Vincenza ConteducaH-Index: 27
#2Elena CastroH-Index: 20
Last. Anna Wingate (UCL: University College London)H-Index: 4
view all 20 authors...
#2Rebeca LozanoH-Index: 4
Last. Elena AlmagroH-Index: 2
view all 20 authors...
#1Isabel AragonH-Index: 4
#2Daniel KhalafH-Index: 7
Last. Ylenia CendonH-Index: 3
view all 18 authors...
#1Elena CastroH-Index: 20
#2Daniela Correia Salles (JHUSOM: Johns Hopkins University School of Medicine)
view all 20 authors...
#1Pasquale Rescigno (University of Naples Federico II)H-Index: 21
#2David Dolling (ICR: Institute of Cancer Research)H-Index: 18
Last. Johann S. de Bono (ICR: Institute of Cancer Research)H-Index: 92
view all 27 authors...
Abstract Background Declines in prostate-specific antigen (PSA) levels at 12 wk are used to evaluate treatment response in metastatic castration-resistant prostate cancer (mCRPC). PSA fall by ≥30% at 4 wk (PSA4w30) has been reported to be associated with better outcome in a single-centre cohort study. Objective To evaluate clinical relevance of early PSA decline in mCRPC patients treated with next-generation hormonal treatments (NGHTs) such as abiraterone and enzalutamide. Design, setting, and p...
2 CitationsSource
#1David LorenteH-Index: 23
#2Elena CastroH-Index: 20
Last. Carlo CattriniH-Index: 4
view all 22 authors...
#1Alexandra Sokolova (UW: University of Washington)H-Index: 3
#2Catherine Handy Marshall (Johns Hopkins University)H-Index: 4
Last. Michael T. Schweizer (Fred Hutchinson Cancer Research Center)H-Index: 21
view all 16 authors...
63Background: Over 10% of men with metastatic prostate cancer (PC) have germline DNA damage response gene alterations; most studies have reported BRCA2 alone or an aggregate of BRCA1, BRCA2 and ATM...
#1Anna S. Trigos (Peter MacCallum Cancer Centre)H-Index: 2
#2Anupama Pasam (Peter MacCallum Cancer Centre)H-Index: 4
Last. Nathan Lawrentschuk (Peter MacCallum Cancer Centre)H-Index: 39
view all 21 authors...
152Background: Prostate cancer (PC) is considered an immunologically ‘cold’ tumor and therefore patients are generally not considered good candidates for immunotherapy. Tumors arising in germline (...
53Background: HRQoL is a relevant endpoint in trials in advanced prostate cancer. An association between HRQoL and OS has been reported. The Functional Assessment of Cancer Therapy-Prostate (FACT-P...